Albert Bourla

Chairman and CEO of @Pfizer. Father. Optimist. Working every day for breakthroughs that change patients’ lives. 🇬🇷🇺🇸

[Albert Bourla @AlbertBourla]

We dosed the first patients in our Phase 3 program for tilrekimig, an investigational trispecific antibody discovered in @Pfizer laboratories, just months after the encouraging Phase 2 results shared earlier this year.

These three studies are the latest of many pivotal starts in an ambitious year for our R&D portfolio. A fourth Phase 2/3 study in COPD is also ongoing.

Thank you to my colleagues working at great speed on this program and to the patients and families now enrolling. I look forward to sharing more soon.

[Albert Bourla @AlbertBourla]

We want @Pfizer to be the most AI-forward company in our industry. That does not come from a central team. It comes when our labs, plants and commercial teams build on one foundation with their own expertise. That is what Dennis is building, quickly. Proud to see it recognized. https://t.co/C6hvQW6sFj

[Atlantic Council @AtlanticCouncil]

On how AI could accelerate medicine development:

I think we can compress the time, improve the probability of success, and see far more medicines succeed in human clinical trials, @Pfizer CEO @AlbertBourla tells @FredKempe at an #ACFrontPage conversation. #ACinNY.

[Concordia @ConcordiaSummit]

Joining us now is @AlbertBourla, CEO, @Pfizer in conversation with @AliceParkNY, Senior Health Correspondent, @TIME to discuss the business of better health at #Concordia26

[Atlantic Council @AtlanticCouncil]

LIVE NOW | @Pfizer CEO @AlbertBourla on AI, health, and innovation in a changing world #ACinNY https://t.co/c6PZ0KHrOP

[Albert Bourla @AlbertBourla]

Business leaders are navigating extraordinary change, and @BizRoundtable has a critical role in bringing us together around the challenges and opportunities ahead. Kristen Silverberg has the experience, judgment and relationships to lead, and I am delighted to see her named CEO. She will build on the strong legacy of Joshua Bolten, who has guided BRT and its members with purpose for the past decade.

[Business Roundtable @BizRoundtable]

Today, BRT Chair @ChuckRobbins announced Kristen Silverberg as BRT’s next President and Chief Executive Officer. Ambassador Silverberg, who currently serves as President and Chief Operating Officer, will succeed current BRT CEO Joshua Bolten when he retires on January 31, 2027. https://t.co/22VXuERjSE

[Albert Bourla @AlbertBourla]

Twenty-five years later, the loss still stings. For many of us, that morning changed our lives forever. Our memories have become history to some 100 million Americans too young to remember a day that reshaped the world they live in.

Though a generation has gone by, we will always remember. New York has been @Pfizer's home since 1849, and we are still just a few miles from where the towers stood.

I am heartened that we all continue uniting to honor those we lost, including two of our own, Jean Marie Collin and Joseph "Joe" DeLuca. We remember Jean and Joe alongside the first responders and the thousands of others lost that day.

We honor them by making this more than a moment we grieve. Our colleagues across 10 U.S. cities will pack meals for families in need this week, and we also continue our annual support of the @Sept11Memorial.

Through our service, we keep memories alive. And we prove that hate will never overcome compassion, unity and resilience.

#NeverForget911

[Albert Bourla @AlbertBourla]

In our industry, time is life. Every big bet we make, in cancer, obesity and AI, comes back to speeding up the delivery of breakthroughs that change patients' lives. Great conversation with @sampjacobs @TIME. https://t.co/XsatFtxm6f

[Albert Bourla @AlbertBourla]

Full results: https://t.co/ZXihMyPULS

[Albert Bourla @AlbertBourla]

Our second quarter results are out today, and I am proud to report another strong quarter of execution. Thank you to my @pfizer colleagues, all of you, for everything behind these results and for your commitment to our purpose: breakthroughs that change patients’ lives.

[Albert Bourla @AlbertBourla]

Congratulations to Spain on a great #WorldCup victory, and to Argentina on an excellent run.

Nobody would call me the biggest football (soccer) fan, but it was an excellent match and the entire tournament has been a great reminder of what becomes possible when the world comes together. Sport can do that in a way not much else can.

With so many games played just a few miles from our headquarters in New York, the tournament also felt close to home. And it carried a lesson. You don't become a champion by hoping your rivals stumble. You become a champion by playing better and scoring more goals. When the competition is strong, you raise your own game. I believe the same is true in science and in our industry.

I have lived and worked in five different countries, and each one taught me something I could not have learned anywhere else. @Pfizer is a global company, and the best thing I ever did for my career was get out into the world, work alongside people different from me and stay open to what they had to teach me.

That includes, of course, our colleagues in Spain, where we have operated for more than 70 years and where we just opened a next-generation supply chain command center in Madrid. Muchas felicidades. We are celebrating with you.

[Albert Bourla @AlbertBourla]

Congratulations to Spain on a great #WorldCup victory, and to Argentina on an excellent run.

Nobody would call me the biggest football (soccer) fan, but it was an excellent match and the entire tournament has been a great reminder of what becomes possible when the world comes together. Sport can do that in a way not much else can.

With so many games played just a few miles from our headquarters in New York, the tournament also felt close to home. And it carried a lesson. You don't become a champion by hoping your rivals stumble. You become a champion by playing better and scoring more goals. When the competition is strong, you raise your own game. I believe the same is true in science and in our industry.

I have lived and worked in five different countries, and each one taught me something I could not have learned anywhere else. @Pfizer is a global company, and the best thing I ever did for my career was get out into the world, work alongside people different from me and stay open to what they had to teach me.

That includes, of course, our colleagues in Spain, where we have operated for more than 70 years and where we just opened a next-generation supply chain command center in Madrid. Muchas felicidades. We are celebrating with you.

[Albert Bourla @AlbertBourla]

https://t.co/MSzECMmj6f

[Albert Bourla @AlbertBourla]

Another strong milestone for people living with MIBC. Our science continues to deliver more targeted options for patients who have been underserved for too long. Grateful to our teams and our partners at @Astellas and @Merck.

[Albert Bourla @AlbertBourla]

America has always been a place where big ideas become breakthroughs that change the world. Pfizer has been part of that story for 177 years, and with AI accelerating discovery, our best science is still ahead of us. #A250 @MariaBartiromo @FoxBusiness https://t.co/gW2kf1CTPd

[Albert Bourla @AlbertBourla]

Only in America could a scientist from Greece rise to lead one of the world's great scientific companies. I have never taken that for granted, and I think about it even more as America turns 250.

This country has always had a gift for making bold bets that changed the world. The moon landing, the internet, the Human Genome Project. These milestones and so many others came from generations of Americans who chose to invest in science and a belief in a brighter future.

Today, America faces a choice once again.

New tools in biology, from how we design medicines to how we manufacture them, have already expanded what is possible for patients. AI will shape what comes next in ways we are only beginning to see.

Tools alone don’t determine outcomes. It requires investing in innovation. It requires committing to shaping future opportunities. The coming decade will determine where great new discoveries occur and where the most ambitious scientists build their life's work.

I want the answer to be here. Other nations have serious scientific ambition, and I welcome it. Competition never scared America. It has always made us better. You don’t win races by trying to hold others back. You win by running faster, running harder.

America’s opportunity is to continue leading by investing more, building more and moving faster. Pfizer will continue doing its part. We were founded in New York in 1849, and we have been competing and betting on American science ever since. We are driven by a single purpose: delivering breakthroughs that change patients' lives.

My wish for America's 250th birthday is simple. Let us choose, once again, to bet on ourselves – and on science. No nation has ever done it better.

🇺🇸 #A250

[Albert Bourla @AlbertBourla]

For the millions of people living with obesity, more options cannot come soon enough, and our R&D team is doing some of the best work I have seen. We look forward to sharing more soon.

[Albert Bourla @AlbertBourla]

We dosed the first participants in VESPER-6, the latest Phase 3 trial of our lead investigational medicine in obesity and started a Phase 2b study testing it in combination with an investigational amylin analog.

[Albert Bourla @AlbertBourla]

My colleague Chris Boshoff, who leads R&D, is featured in @sciam on the state of American science. He calls it extraordinary, and accelerating. He's right. We're living through a scientific renaissance, and I'm optimistic about what American innovation can do for patients. https://t.co/usuRmeHxCR

[Albert Bourla @AlbertBourla]

Leading in biomedical innovation comes down to one thing. America should be the best place in the world to discover and test new medicines. Faster trial starts, with no compromise on the science, do exactly that. Good to see this progress from @HHSGov.

[HHS @HHSGov]

Today, HHS launched a department-wide effort to restore U.S. leadership in clinical trials by reducing unnecessary barriers, accelerating research, expanding patient access to studies, and strengthening America’s biomedical innovation ecosystem.

From FDA and NIH to ARPA-H and ONC, HHS is working to help bring more clinical research, investment, and medical breakthroughs back to the United States.

Read More:

https://t.co/1HPNxBYRWj